Comparative role of acetylation along c-SRC/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 10, 2011, Pages 1767-1776

  Bendinelli, Paola ^a   Maroni, Paola ^b   Matteucci, Emanuela ^a   Desiderio, Maria Alfonsina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Bone metastasis; Breast cancer; C Src; CXCR4; HDACs

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ACETYLATION; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; BREAST CELL; CANCER INVASION; CARCINOMA CELL; CELL MIGRATION; CELL STRAIN MDA MB231; CYTOSOL; ELECTROPHORETIC MOBILITY; ENVIRONMENT; EPIGENETICS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR MECHANICS; ONCOGENE SRC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEADY STATE;

ACETYLATION; ACETYLTRANSFERASES; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHENOTYPE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 80051799987     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.06.004     Document Type: Article

References (60)

1. Araujo J., Logothetis C. Targeting Src signaling in metastatic bone disease. Int. J. Cancer 2009, 124:1-6.
2. Talamonti M.S., Roh M.S., Curley S.A., Gallick G.E. Increase in activity and level of pp 60c-src in progressive stages of human colon cancer. J. Clin. Invest. 1993, 91:53-60.
3. Cartwright C.A., Coad C.A., Egbert B.M. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J. Clin. Invest. 1994, 93:509-515.
4. Mao W., Irby R., Coppola D., Fu L., Wloch M., Turner J., Yu H., Garcia R., Jove R., Yetman T.J. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997, 15:3083-3090.
5. Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A., Gallick G.E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94:344-351.
6. Rucci N., Recchia I., Angelucci A., Alamanou M., Del Fattore A., Fortunati D., Susa M., Fabbro D., Bologna M., Teti A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J. Pharmacol. Exp. Ther. 2006, 318:161-172.
7. Zhang X.H., Wang Q., Gerald W., Huidis C.A., Norton L., Smid M., Fœkens J.A., Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
8. Matteucci E., Ridolfi E., Maroni P., Bendinelli P., Desiderio M.A. c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor-dependent decrease of CXCR4 expression in highly invasive breast tumor cells. Mol. Cancer Res. 2007, 5:833-845.
9. Previdi S., Maroni P., Matteucci E., Broggini M., Bendinelli P., Desiderio M.A. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways. Eur. J. Cancer 2010, 46:1679-1691.
10. Maroni P., Matteucci E., Luzzati A., Perrucchini G., Bendinelli P., Desiderio M.A. Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma. Breast Cancer Res. Treat. 2011, 10.1007/s10549-010-1240.
11. Ridolfi E., Matteucci E., Maroni P., Desiderio M.A. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br. J. Cancer 2008, 99:1323-1634.
12. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., Mcclanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegu E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
13. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
14. Cabioglu N., Sahin A.A., Morandi P., Meric-Bernstam F., Islam R., Lin H.Y., Bucana C.D., Gonzalez-Angulo A.M., Hortobagyi G.N., Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 2009, 20:1013-1029.
15. Busillo J.M., Armando S., Sengupta R., Meucci O., Buovier M., Benovic J.L. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J. Biol. Chem. 2010, 285:7805-7817.
16. Salvucci O., Bouchard A., Baccarelli A., Deschênes J., Sauter G., Simon R., Bianchi R., Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat. 2006, 97:275-283.
17. Hassan S., Ferrario C., Saragovi U., Quenneville L., Gaboury L., Baccarelli A., Salvucci O., Basik M. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am. J. Pathol. 2009, 175:66-73.
18. Shim H., Lau S.K., Devi S., Yoon Y., Cho H.T., Liang Z. Lower expression of CXCR4 in lymph node metastasis than in primary breast cancers: potential regulation by ligand-dependent degradation of HIF-1α. Biochem. Biophys. Res. Commun. 2006, 346:252-258.
19. Matteucci E., Locati M., Desiderio M.A. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp. Cell Res. 2005, 310:176-185.
20. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
21. Smith M.C.P., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., Luker G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004, 64:8604-8612.
22. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65:967-971.
23. Cabioglu N., Summy J., Miller C., Parikh N.U., Sahin A.A., Tuzlali S., Pumiglia K., Gallick G.E., Price J.E. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005, 65:6493-6497.
24. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
25. Kim T.Y., Bang Y.J., Robertson K.D. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006, 1:14-23.
26. Kostyniuk C.L., Dehm S.M., Batten D., Bonham K. The ubiquitous and tissue specific promoter of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 2002, 21:6340-6347.
27. Wade P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 2001, 10:693-698.
28. Forsberg E.C., Bresnick E.H. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 2001, 23:820-830.
29. Buggy Y., Maguire T.M., McGreal G., McDermott E., Hill A.D.K., O'Higgins N., Duffy M.J. Overexpression of the Ets-1 transcription factor in human breast cancer. Br. J. Cancer 2004, 91:1308-1315.
30. Furlan A., Vercamer C., Desbiens X., Pourtier A. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J. Cell. Physiol. 2008, 215:782-793.
31. Gimona M., Buccione R., Courtneidge S.A., Linder S. Assembly and biological role of podosomes and invadopodia. Curr. Opin. Cell Biol. 2008, 20:235-241.
32. Smith-Pearson P.S., Greuber E.L., Yogalingam G., Pendergast A.M. Abl kinase are required for invadopodia formation and chemokine-induced invasion. J. Biol. Chem. 2010, 285:40201-40211.
33. Jovanovic J., Rønnemberg J.A., Tost J., Kristensen V. The epigenetic of breast cancer. Mol. Oncol. 2010, 4:242-254.
34. Maroni P., Bendinelli P., Matteucci E., Desiderio M.A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-κB. Carcinogenesis 2007, 28:267-279.
35. Bendinelli P., Matteucci E., Maroni P., Desiderio M.A. NF-κB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol. Cancer Res. 2009, 7:1328-1341.
36. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 1995, 7:728-735.
37. Guo Y., Pakneshan P., Gladu J., Slack A., Szyf M., Rabbani S.A. Regulation of DNA methylation in human breast cancer. J. Biol. Chem. 2002, 277:41571-41579.
38. Wolf K., Mazo I., Leung H., Engelke K., von Adrian U.H., Deryugina E.I., Strongin A.Y., Bröcker E.-B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-ameboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
39. Cameron E.E., Bachman K.E., Myöhänen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
40. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., Shim H. Inhibition of breast cancer metastasis by selective synthetic peptide against CXCR4. Cancer Res. 2004, 64:4302-4308.
41. Malik R., Marchese A. Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Mol. Biol. Cell 2010, 21:2529-2541.
42. Berlin I., Higginbotham K.M., Dise R.S., Sierra M.I., Nash P.D. The deubiquitinating enzyme USP8 promotes trafficking and degradation of the chemokine receptor 4 at the sorting endosome. J. Biol. Chem. 2010, 285:37895-37908.
43. Dittmer J. The biology of the Ets1 Proto-Oncogene. Mol. Cancer 2003, 2:1-21.
44. Yetman T.J. A renaissance for Src. Nat. Rev. Cancer 2004, 4:470-480.
45. Fry C.J., Farnham P.J. Context-dependent transcriptional regulation. J. Biol. Chem. 1999, 274:29583-29586.
46. Woerner B.M., Warrington N.M., Kung A.L., Perry A., Rubin J.B. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res. 2005, 65:11392-11399.
47. Katoh M., Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFβ, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol. 2010, 36:415-420.
48. Matteucci E., Bendinelli P., Desiderio M.A. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 2009, 30:937-945.
49. Gobeil F., Fortier A., Zhu T., Bossolasco M., Leduc M., Grandbois M., Heveker N., Bkaily G., Chemtob S., Barbaz D. G-protein-coupled receptors signaling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol. 2006, 84:287-297.
50. Matteucci E., Ridolfi E., Desiderio M.A. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells. Cell. Mol. Life Sci. 2006, 63:2016-2026.
51. Kumar A., Kremer K.N., Dominguez D., Tadi M., Hedin K.E. Gα13 and Rho mediate endosomal trafficking of CXCR4 into Rab11+ vesicles upon stromal cell-derived factor-1 stimulation. J. Immunol. 2011, 186:951-958.
52. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14:171-179.
53. Scita G., Di Fiore P.P. The endocytic matrix. Nature 2010, 463:464-473.
54. Wang L., Wang Z., Yang B., Yang Q., Wang L., Sun Y. CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma. Oncol. Rep. 2009, 22:1333-1339.
55. Chetram M.A., Odero-Marah V., Hinton C.V. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells. Mol. Cancer Res. 2011, 9:90-102.
56. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1:19-25.
57. Nelson M.L., Kang H.-S., Lee G.M., Blaszczak A.G., Lau D.K.W., Mcintosh L.P., Graves B.J. Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc. Natl Acad. Sci. 2010, 107:10026-10031.
58. Teicher B.A., Fricker S.P. CXCL12 (SDF1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16:2927-2931.
59. Furusato B., Mohamed A., Uhlèn M., Rhim J.S. CXCR4 and cancer. Pathol. Int. 2010, 60:497-505.
60. Stresemann C., Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 2008, 123:8-13.